Drugs / EGFR BATs
EGFR BATs
also known as
anti-EGFR bispecific-armed T cells · anti-EGFR-bispecific antibody armed activated T-cells · BATs
Cell therapy targets EGFR
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04137536 | Oct 2019 → Apr 2027 expected | pancreatic adenocarcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03344250 | Mar 2018 → Dec 2021 | glioblastoma | University of Virginia | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03269526 | Jul 2017 → Jun 2023 | pancreatic adenocarcinoma | University of Virginia | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07343986 Comparator | Mar 2026 → Dec 2027 expected | brain glioblastoma | University of Virginia | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFR BATs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03269526 ↗ |
| Known as | anti-EGFR bispecific-armed T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07343986 ↗ |
| Known as | anti-EGFR-bispecific antibody armed activated T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04137536 ↗ |
| Known as | BATs | “bispecific antibody armed T cells (BATs)” NCT03269526 ↗ |
| Modality | Cell therapy | “activated T cells” NCT03269526 ↗ |
| Route | Intravenous | “intravenously infused EGFR BATs” PMID 38263486 ↗ Jan 2024 |
| Target | EGFR | “anti-EGFR” NCT03269526 ↗ |